About

Staff transport cell samples

The USC/CHLA Cell Therapy Program (CTP) was initiated in 2021 with investments from the Keck School of Medicine (KSOM) of USC, Keck Medicine (KM) of USC and Children’s Hospital Los Angeles (CHLA).

The primary goal of the program is to promote clinical translation of a growing body of pre-clinical work in cell and gene therapy at both institutions and maximize success of the entire translational paradigm. By generating a mature translational ecosystem with state-of-the-art laboratories, hands-on support and educational offerings, we provide researchers with proficient guidance to successfully translate early-stage ideas into clinically viable products in a robust and cost-effective manner.

Ultimately, CTP offers researchers/collaborators a meaningful partnership and wide range of services, from strategic planning to product manufacturing and quality control testing. Always aligning the scientific and clinical objectives of the project to Good Manufacturing Practices (GMP) and other relevant regulatory requirements, we develop and optimize vein-to-vein workflows and identify improvement opportunities in the process. We are also interested in partnering with external stakeholders to provide them with a one-stop shop solution that utilizes some of the most advanced analytical and proof-of-principle approaches in the sector.

The USC/CHLA CTP is part of the CIRM alpha clinics network.